JP Morgan resumed coverage on BioCryst Pharma with a new price target
$BCRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JP Morgan resumed coverage of BioCryst Pharma with a rating of Overweight and set a new price target of $10.00